389617-38-3 Usage
Description
7-Azabicyclo[2.2.1]heptane-7-carboxylic acid, 2-formyl-, ethyl ester is a pyrrolidine-based organic compound that serves as a versatile building block in pharmaceutical and chemical research for the synthesis of various compounds. Its potential biological activities and pharmacological properties make it a valuable component in the production of pharmaceuticals, as well as in the development of new drugs and the synthesis of bioactive molecules. The ethyl ester form enhances its ease of handling, transport, and use as a reagent in organic chemistry synthesis.
Uses
Used in Pharmaceutical Industry:
7-Azabicyclo[2.2.1]heptane-7-carboxylic acid, 2-formyl-, ethyl ester is used as a building block for the synthesis of pharmaceuticals due to its potential biological activities and pharmacological properties.
Used in Chemical Research:
7-Azabicyclo[2.2.1]heptane-7-carboxylic acid, 2-formyl-, ethyl ester is used as a reagent in organic chemistry synthesis, facilitating the development of new drugs and the synthesis of bioactive molecules.
Used in Drug Development:
7-Azabicyclo[2.2.1]heptane-7-carboxylic acid, 2-formyl-, ethyl ester is used as a component in the development of new drugs, leveraging its potential biological activities and pharmacological properties to contribute to innovative medicinal compounds.
Check Digit Verification of cas no
The CAS Registry Mumber 389617-38-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,8,9,6,1 and 7 respectively; the second part has 2 digits, 3 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 389617-38:
(8*3)+(7*8)+(6*9)+(5*6)+(4*1)+(3*7)+(2*3)+(1*8)=203
203 % 10 = 3
So 389617-38-3 is a valid CAS Registry Number.
389617-38-3Relevant articles and documents
Pharmaceutical compositions and methods for use
-
, (2008/06/13)
Pharmaceutical compositions incorporate compounds that are capable of affecting nicotinic cholinergic receptors. A wide variety of conditions and disorders, and particularly conditions and disorders associated with dysfunction of the central and autonomic nervous systems can be treated using pharmaceutical compositions incorporating compounds in which an aromatic ring is bridged with an ethylenic or acetylenic unit to an azabicyclic moiety.
